{"schema":"rootz.ai/filing-signals/v1","query":{"ticker":"FEMY","limit":50},"count":50,"signals":[{"ticker":"FEMY","company":"FEMASYS INC","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"ai_adoption","strength":100,"match_count":31,"context":"pliance with Nasdaq's continued listing requirements and our common stock could become subject to delisting from Nasdaq if we fail to regain compliance. Risks Related to Discovery and Development Enrollment and retention of subjects in clinical trials is an expensive and time-consuming process. Our current U.S. product candidate is in late-stage development. 2 Table of Contents We are substantially d","filed_date":"2026-03-31","accession":"0001140361-26-012375","full_text":"https://origin.rootz.global/static/filing/0001140361-26-012375.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"FEMY","company":"FEMASYS INC","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":62,"context":"d and manage our inventory. We manufacture and assemble components for our products and U.S. product candidate, and a loss or degradation in performance of our manufacturing capabilities could have a material adverse effect on our business. We rely on a limited number of third-party suppliers for components for our products and U.S. product candidate. Performance issues, service interruptions or price increases by our s","filed_date":"2026-03-31","accession":"0001140361-26-012375","full_text":"https://origin.rootz.global/static/filing/0001140361-26-012375.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"FEMY","company":"FEMASYS INC","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":25,"context":"ffecting the business, properties, management, financial position, stockholders equity, results of operations or prospects of the Company, whether or not arising in the ordinary course of business (a Material Adverse Effect); (ii) the Company has not entered into any transaction or agreement (whether or not in the ordinary course of business) that is material to the Company or incurred any liability or obligation, direc","filed_date":"2025-08-27","accession":"0001140361-25-032806","full_text":"https://origin.rootz.global/static/filing/0001140361-25-032806.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"FEMY","company":"FEMASYS INC","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":26,"context":"ffecting the business, properties, management, financial position, stockholders equity, results of operations or prospects of the Company, whether or not arising in the ordinary course of business (a Material Adverse Effect); (ii) the Company has not entered into any transaction or agreement (whether or not in the ordinary course of business) that is material to the Company or incurred any liability or obligation, direc","filed_date":"2025-06-02","accession":"0001140361-25-021030","full_text":"https://origin.rootz.global/static/filing/0001140361-25-021030.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"FEMY","company":"FEMASYS INC","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":100,"match_count":23,"context":"any proposal to be brought before the meeting by stockholders of Femasys, and we have not received notice of any such proposals. If any other matter were to come before the meeting, the proxy holders appointed by our board of directors will have the discretion to vote on those matters for you. |  | |  Q: |  How does the board of directors recommend I vote on these proposals? |  | |  A: |  Our board of directors recommends that you","filed_date":"2025-04-28","accession":"0001140361-25-016047","full_text":"https://origin.rootz.global/static/filing/0001140361-25-016047.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"FEMY","company":"FEMASYS INC","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"ai_adoption","strength":100,"match_count":32,"context":"r net operating losses and research and development credit carryforwards to offset future taxable income, if any, may be subject to certain limitations. Risks Related to Discovery and Development Enrollment and retention of subjects in clinical trials is an expensive and time-consuming process. The FDA may not allow us to continue the ongoing pivotal trial for FemBloc Premarket approval (PMA) due to","filed_date":"2025-03-27","accession":"0001140361-25-010598","full_text":"https://origin.rootz.global/static/filing/0001140361-25-010598.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"FEMY","company":"FEMASYS INC","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":57,"context":"demand and manage our inventory. We manufacture and assemble components for our products and product candidate, and a loss or degradation in performance of our manufacturing capabilities could have a material adverse effect on our business. We rely on a limited number of third-party suppliers for components for our products and product candidate. Performance issues, service interruptions or price increases by our shippi","filed_date":"2025-03-27","accession":"0001140361-25-010598","full_text":"https://origin.rootz.global/static/filing/0001140361-25-010598.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"FEMY","company":"FEMASYS INC","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"ai_adoption","strength":100,"match_count":14,"context":"clearance from the FDA for FemaSeed for intratubal insemination to market in the United States. A pivotal clinical trial was still ongoing at the time of receiving regulatory clearance, however, enrollment was completed in November 2023. In June 2024, the Company received European Union Medical Device Regulation (EU MDR) certificates and CE Mark certification for four products: FemaSeed, FemVue, Fem","filed_date":"2024-08-08","accession":"0001140361-24-036299","full_text":"https://origin.rootz.global/static/filing/0001140361-24-036299.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"FEMY","company":"FEMASYS INC","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":100,"match_count":17,"context":"any proposal to be brought before the meeting by stockholders of Femasys, and we have not received notice of any such proposals. If any other matter were to come before the meeting, the proxy holders appointed by our board of directors will have the discretion to vote on those matters for you. | | | Q: | How does the board of directors recommend I vote on these proposals? | | | A: | Our board of directors recommends that you vote","filed_date":"2024-06-07","accession":"0001140361-24-029274","full_text":"https://origin.rootz.global/static/filing/0001140361-24-029274.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"FEMY","company":"FEMASYS INC","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"ai_adoption","strength":100,"match_count":14,"context":"clearance from the FDA for FemaSeed for intratubal insemination to market in the United States. A pivotal clinical trial was still ongoing at the time of receiving regulatory clearance, however, enrollment was completed in November 2023. FemVue, a solution that enables fallopian tube assessment with ultrasound as an alternative to the radiologic approach (hysterosalpingogram) for the diagnosis of in","filed_date":"2024-05-09","accession":"0001140361-24-025068","full_text":"https://origin.rootz.global/static/filing/0001140361-24-025068.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"FEMY","company":"FEMASYS INC","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":100,"match_count":13,"context":"one Form 4 filing for Ms. Thomas on November 1, 2023 reporting a transaction that occurred on October 10, 2023. 6 [Table of Contents](#TABLEOFCONTENTS) |  Item 11. |  Executive Compensation. |  | Our named executive officers for 2023, which consist of our principal executive officer and the next two most highly compensated executive officers, are: Kathy Lee-Sepsick, our founder, President, Chief Executive Officer and Di","filed_date":"2024-04-26","accession":"0001140361-24-022556","full_text":"https://origin.rootz.global/static/filing/0001140361-24-022556.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"FEMY","company":"FEMASYS INC","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"ai_adoption","strength":100,"match_count":42,"context":"to use our net operating losses and research and development credit carryforwards to offset future taxable income may be subject to certain limitations. Risks Related to Discovery and Development Enrollment and retention of subjects in clinical trials is an expensive and time-consuming process. The FDA may not allow us to continue the ongoing pivotal trial for FemBloc Premarket approval (PMA) due to","filed_date":"2024-03-28","accession":"0001140361-24-016230","full_text":"https://origin.rootz.global/static/filing/0001140361-24-016230.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"FEMY","company":"FEMASYS INC","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":45,"context":"emand and manage our inventory. We manufacture and assemble components for our products and product candidates, and a loss or degradation in performance of our manufacturing capabilities could have a material adverse effect on our business. We rely on a limited number of third-party suppliers for components for our products and product candidates. Performance issues, service interruptions or price increases by our shipp","filed_date":"2024-03-28","accession":"0001140361-24-016230","full_text":"https://origin.rootz.global/static/filing/0001140361-24-016230.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"FEMY","company":"FEMASYS INC","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":100,"match_count":21,"context":"-CEO of Salem Partners, LLC since 1997 and Salem Partners Wealth Management, LLC since 2004. Mr.Dyett helped raise several rounds of venture capital for Adams Respiratory Therapeutics, Inc. which was purchased for $2.3billion by Reckitt Benckiser in 2008. Mr.Dyett helped launch ZS Pharma, Inc., a specialty  15 [TABLE OF CONTENTS](#TOC) pharmaceutical company. ZS Pharma, Inc. completed a successful initial public","filed_date":"2023-05-15","accession":"0001140361-23-024471","full_text":"https://origin.rootz.global/static/filing/0001140361-23-024471.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"FEMY","company":"FEMASYS INC","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"ai_adoption","strength":100,"match_count":45,"context":"ing liquidity, could adversely affect our current and projected business operations and our financial condition and results of operations. |  | Risks Related to Discovery and Development |  |  |  Enrollment and retention of subjects in clinical trials is an expensive and time-consuming process. |  | |  |  |  The FDA may not allow us to initiate a pivotal trial for FemBloc Premarket approval (PMA) due","filed_date":"2023-03-30","accession":"0001140361-23-014668","full_text":"https://origin.rootz.global/static/filing/0001140361-23-014668.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"FEMY","company":"FEMASYS INC","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":34,"context":"ge our inventory. |  | |  |  |  We manufacture and assemble components for our products and product candidates, and a loss or degradation in performance of our manufacturing capabilities could have a material adverse effect on our business. |  | |  |  |  We rely on a limited number of third-party suppliers for components for our products. |  | |  |  |  Performance issues, service interruptions or price increases by our","filed_date":"2023-03-30","accession":"0001140361-23-014668","full_text":"https://origin.rootz.global/static/filing/0001140361-23-014668.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"FEMY","company":"FEMASYS INC","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":100,"match_count":19,"context":"ril 2015. Mr.Adams has served as Chief Executive Officer of Adams Respiratory Therapeutics Inc. and served as its President from 2003 to 2008. Adams Respiratory developed Mucinex and was subsequently acquired by Reckitt Benckiser for $2.3billion. Mr.Adams founded and has managed Legacy Capital Partners, LLC, an investment management and private equity firm focused on healthcare technology and pharmaceutical development, since 2009.","filed_date":"2022-04-26","accession":"0001140361-22-015981","full_text":"https://origin.rootz.global/static/filing/0001140361-22-015981.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"FEMY","company":"FEMASYS INC","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"ai_adoption","strength":100,"match_count":30,"context":"operating losses and research and development credit carryforwards to offset future taxable income may be subject to certain limitations. |  | Risks Related to Discovery and Development |  |  |  Enrollment and retention of subjects in clinical trials is an expensive and time-consuming process. |  | |  |  |  The FDA may not allow us to initiate a pivotal trial for FemBloc Premarket approval (PMA) due","filed_date":"2022-03-24","accession":"0001140361-22-011032","full_text":"https://origin.rootz.global/static/filing/0001140361-22-011032.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"FEMY","company":"FEMASYS INC","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":32,"context":"ge our inventory. |  | |  |  |  We manufacture and assemble components for our products and product candidates, and a loss or degradation in performance of our manufacturing capabilities could have a material adverse effect on our business. |  | |  |  |  We rely on a limited number of third-party suppliers for components for our products. |  | |  |  |  Performance issues, service interruptions or price increases by our","filed_date":"2022-03-24","accession":"0001140361-22-011032","full_text":"https://origin.rootz.global/static/filing/0001140361-22-011032.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"FEMY","company":"FEMASYS INC","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"ai_adoption","strength":100,"match_count":21,"context":"1, the Company executed two Promissory Notes with AFCO (AFCO notes) to finance certain insurance premiums totaling $64,842, requiring the Company to pay $16,210 in down payments and make monthly installment payments. The annual interest rate is 10.5% and the current monthly installment payments total $6,094, which represents principal and interest. The final installment payments are due October 15, 2","filed_date":"2021-08-11","accession":"0001140361-21-027946","full_text":"https://origin.rootz.global/static/filing/0001140361-21-027946.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"FEMY","company":"FEMASYS INC","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":29,"context":"other information in this Quarterly Report on Form 10-Q, including our financial statements and related notes, before investing in our common stock. The realization of any of these risks could have a significant adverse effect on our reputation, business, financial condition, results of operations and growth, and our ability to accomplish our strategic objectives. In that event, the trading price of our common stock could","filed_date":"2021-08-11","accession":"0001140361-21-027946","full_text":"https://origin.rootz.global/static/filing/0001140361-21-027946.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"FEMY","company":"FEMASYS INC","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":29,"context":"nge in short-term debt or long-term debt of the Company, or any dividend or distribution of any kind declared, set aside for payment, paid or made by the Company on any class of capital stock, or any material adverse effect, or any development that would reasonably be expected to result in a material adverse effect (A) on the legality, validity or enforceability of any Transaction Document (as defined below), (B) on the","filed_date":"2026-08-11","accession":"0001140361-26-032247","full_text":"https://origin.rootz.global/static/filing/0001140361-26-032247.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"FEMY","company":"FEMASYS INC","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"ai_adoption","strength":88,"match_count":11,"context":"0(k) clearance from the FDA for FemaSeed intratubal insemination to market in the United States. A pivotal clinical trial was still ongoing at the time of receiving regulatory clearance, however, enrollment was completed in November 2023. In June 2024, the Company received European Union Medical Device Regulation (EU MDR) certificates and CE Mark certification for four products: FemaSeed, FemVue, Fem","filed_date":"2024-11-12","accession":"0001140361-24-046038","full_text":"https://origin.rootz.global/static/filing/0001140361-24-046038.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"FEMY","company":"FEMASYS INC","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"ai_adoption","strength":72,"match_count":9,"context":"the Company announced the notice of allowance for a new U.S. patent application covering use of FemBloc for female permanent birth control. In August 2023 the Company announced the initiation of enrollment for the pivotal clinical trial of FemBloc. FemaSeed (FemaSeed), a solution which enables intratubal artificial insemination to provide a lower cost option to in vitro fertilization methods, receiv","filed_date":"2023-11-14","accession":"0001140361-23-053090","full_text":"https://origin.rootz.global/static/filing/0001140361-23-053090.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"FEMY","company":"FEMASYS INC","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"ai_adoption","strength":72,"match_count":9,"context":"ds, received approval in April 2021 from the FDA on its IDE and the clinical trial was initiated in July 2021. An updated trial design received approval in October 2022 from the FDA and the trial enrollment is ongoing. FemaSeed is approved for sale in Canada. FemVue (FemVue), a solution that enables fallopian tube assessment with ultrasound as an alternative to the radiologic approach (hysterosalping","filed_date":"2023-08-10","accession":"0001140361-23-038918","full_text":"https://origin.rootz.global/static/filing/0001140361-23-038918.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"FEMY","company":"FEMASYS INC","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":58,"match_count":6,"context":"l have the meaning specified in the preamble to this Agreement. Lien shall mean a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right, or other restriction. Material Adverse Effect shall mean any effect on the business, operations, properties, or financial condition of the Company that is material and adverse to the Company and/or any condition, circumstance, or situation that","filed_date":"2025-07-03","accession":"0001140361-25-024878","full_text":"https://origin.rootz.global/static/filing/0001140361-25-024878.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"FEMY","company":"FEMASYS INC","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"ai_adoption","strength":56,"match_count":7,"context":"eding trading day)). The terms of each such award will be set forth in a written award agreement between the non-employee director and us, which will generally provide for vesting in three equal installments following the date of grant (such that such award will vest in full on the third anniversary of the date of grant subject to continued service). Each such award will vest in full immediately prio","filed_date":"2025-04-28","accession":"0001140361-25-016047","full_text":"https://origin.rootz.global/static/filing/0001140361-25-016047.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"FEMY","company":"FEMASYS INC","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"ai_adoption","strength":48,"match_count":6,"context":"2 brhc10043970_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Femasys Inc. Announces Financial Results for the Third Quarter Ended September 30, 2022 and Provides Corporate Update --FemaSeed de novo trial enrollment accelerates with strategic trial design update to focus on male factor infertility-- --Company remains on track to file an Investigational Device Exemption (IDE) for a pivotal trial to support a P","filed_date":"2022-11-10","accession":"0001140361-22-040811","full_text":"https://origin.rootz.global/static/filing/0001140361-22-040811.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"FEMY","company":"FEMASYS INC","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"ai_adoption","strength":48,"match_count":6,"context":"1, the Company executed two Promissory Notes with AFCO (AFCO notes) to finance certain insurance premiums totaling $64,842, requiring the Company to pay $16,210 in down payments and make monthly installment payments. The annual interest rate is 10.5% and the current monthly installment payments total $6,094, which represents principal and interest. The final installment payments were paid on October","filed_date":"2021-11-12","accession":"0001140361-21-037639","full_text":"https://origin.rootz.global/static/filing/0001140361-21-037639.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"FEMY","company":"FEMASYS INC","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":40,"match_count":5,"context":"under, and a payment or benefit provided for in this Agreement would be subject to additional tax under Code Section 409A if such payment or benefit is paid within six (6) months after the Executives separation from service (within the meaning of Code Section 409A), then such payment or benefit required under this Agreement (i) shall not be paid (or commence) during the six-month period immediately following the","filed_date":"2026-04-01","accession":"0001140361-26-012538","full_text":"https://origin.rootz.global/static/filing/0001140361-26-012538.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"FEMY","company":"FEMASYS INC","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"platform_shift","strength":40,"match_count":5,"context":"with federal and state regulations. If treatment guidelines for permanent birth control or other womens healthcare treatments change or the standard of care evolves, we may need to redesign and seek new marketing authorization from the FDA for one or more of our products. There may be misuse or off-label use of our products in the marketplace. Our products may cause or contribute to adverse medical events","filed_date":"2026-03-31","accession":"0001140361-26-012375","full_text":"https://origin.rootz.global/static/filing/0001140361-26-012375.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"FEMY","company":"FEMASYS INC","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"ai_adoption","strength":40,"match_count":5,"context":"O) In July 2025, the Company executed a promissory note with AFCO to finance certain insurance premiums totaling $367,450, requiring the Company to pay $31,672 in a down payment and make monthly installment payments. The annual interest rate was 7.44% and the monthly installment is $31,672, which represents principal and interest.  As of September 30, 2025, and December 31, 2024, there were principal","filed_date":"2025-11-14","accession":"0001140361-25-042308","full_text":"https://origin.rootz.global/static/filing/0001140361-25-042308.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"FEMY","company":"FEMASYS INC","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":40,"match_count":5,"context":"ach remains uncured for a period of two (2) consecutive Trading Days; provided, however, only if such breach, in either case, would, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect; or (xiv) any Event of Default (as defined in the Other Notes) occurs with respect to any Other Notes. (b) Notice of an Event of Default; Redemption Right. Upon the occurrence of an Event of Default","filed_date":"2025-11-07","accession":"0001140361-25-041180","full_text":"https://origin.rootz.global/static/filing/0001140361-25-041180.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"FEMY","company":"FEMASYS INC","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"platform_shift","strength":40,"match_count":5,"context":"e with federal and state regulations. If treatment guidelines for permanent birth control or other women healthcare treatments change or the standard of care evolves, we may need to redesign and seek new marketing authorization from the FDA for one or more of our products. There may be misuse or off-label use of our products in the marketplace. Our products may cause or contribute to adverse medical events","filed_date":"2025-03-27","accession":"0001140361-25-010598","full_text":"https://origin.rootz.global/static/filing/0001140361-25-010598.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"FEMY","company":"FEMASYS INC","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"platform_shift","strength":40,"match_count":5,"context":"e with federal and state regulations. If treatment guidelines for permanent birth control or other women healthcare treatments change or the standard of care evolves, we may need to redesign and seek new marketing authorization from the FDA for one or more of our products. There may be misuse or off-label use of our products in the marketplace. Our products may cause or contribute to adverse medical events","filed_date":"2024-03-28","accession":"0001140361-24-016230","full_text":"https://origin.rootz.global/static/filing/0001140361-24-016230.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"FEMY","company":"FEMASYS INC","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"ai_adoption","strength":40,"match_count":5,"context":"214 **Logo:** https://api.massive.com/v1/reference/company-branding/ZmVtYXN5cy5jb20/images/2025-04-04_logo.svg --- EX-99.1 2 brhc20056945_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Femasys Initiates Enrollment in Pivotal Trial of its Permanent Birth Control Candidate FemBloc - First of its kind, non-surgical, permanent birth control option begins enrollment in landmark trial - ATLANTA, August 3, 2023 Fe","filed_date":"2023-08-03","accession":"0001140361-23-037776","full_text":"https://origin.rootz.global/static/filing/0001140361-23-037776.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"FEMY","company":"FEMASYS INC","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"platform_shift","strength":40,"match_count":5,"context":"and state regulations. |  | |  |  |  If treatment guidelines for permanent birth control or other women healthcare treatments change or the standard of care evolves, we may need to redesign and seek new marketing authorization from the FDA for one or more of our products. |  | |  |  |  There may be misuse or off-label use of our products in the marketplace. |  | |  |  |  Our products may cause or contribut","filed_date":"2023-03-30","accession":"0001140361-23-014668","full_text":"https://origin.rootz.global/static/filing/0001140361-23-014668.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"FEMY","company":"FEMASYS INC","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"ai_adoption","strength":40,"match_count":5,"context":"O) In June 2022, the Company executed a promissory note with AFCO to finance certain insurance premiums totaling $465,380, requiring the Company to pay $47,539 in a down payment and make monthly installment payments. The annual interest rate is 5.71% and the monthly installment is $47,539, which represents principal and interest. As of September 30, 2022 and December 31, 2021, the principal balance o","filed_date":"2022-11-10","accession":"0001140361-22-040812","full_text":"https://origin.rootz.global/static/filing/0001140361-22-040812.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"FEMY","company":"FEMASYS INC","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"platform_shift","strength":40,"match_count":5,"context":"and state regulations. |  | |  |  |  If treatment guidelines for permanent birth control or other women healthcare treatments change or the standard of care evolves, we may need to redesign and seek new marketing authorization from the FDA for one or more of our products. |  | |  |  |  There may be misuse or off-label use of our products in the marketplace. |  | |  |  |  Our products may cause or contribut","filed_date":"2022-03-24","accession":"0001140361-22-011032","full_text":"https://origin.rootz.global/static/filing/0001140361-22-011032.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"FEMY","company":"FEMASYS INC","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"margin_pressure","strength":32,"match_count":4,"context":"thcare practitioner adoption of our FemaSeed product in the U.S.; Changes in coverage policies by third-party payors that affect the U.S. reimbursement of procedures using our products; Unanticipated pricing pressure; The hiring, retention and continued productivity of sales representatives for domestic commercial team; Our ability to expand the geographic reach of our sales and marketing efforts; Our ability to","filed_date":"2026-03-31","accession":"0001140361-26-012375","full_text":"https://origin.rootz.global/static/filing/0001140361-26-012375.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"FEMY","company":"FEMASYS INC","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"ai_adoption","strength":32,"match_count":4,"context":"0/images/2025-04-04_logo.svg --- EX-99.1 2 ef20069346_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Femasys Announces Financial Results for Year Ended December 31, 2025 and Provides Corporate Update -- Enrollment underway in FDA-authorized FINALE pivotal trial demonstrating execution toward FemBloc U.S. approval -- ATLANTA, March 31, 2026 Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making f","filed_date":"2026-03-31","accession":"0001140361-26-012346","full_text":"https://origin.rootz.global/static/filing/0001140361-26-012346.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"FEMY","company":"FEMASYS INC","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"margin_pressure","strength":32,"match_count":4,"context":"titioner adoption of our FemaSeed product; |  | |  |  |  Changes in coverage policies by third-party payors that affect the reimbursement of procedures using our products; |  | |  |  |  Unanticipated pricing pressure; |  | |  |  |  The hiring, retention and continued productivity of sales representatives; |  | |  |  |  Our ability to expand the geographic reach of our sales and marketing efforts; |  | |  |  |  Ou","filed_date":"2025-03-27","accession":"0001140361-25-010598","full_text":"https://origin.rootz.global/static/filing/0001140361-25-010598.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"FEMY","company":"FEMASYS INC","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"margin_pressure","strength":32,"match_count":4,"context":"hysician adoption of our FemaSeed product; |  | |  |  |  Changes in coverage policies by third-party payors that affect the reimbursement of procedures using our products; |  | |  |  |  Unanticipated pricing pressure; |  | |  |  |  The hiring, retention and continued productivity of sales representatives; |  | |  |  |  Our ability to expand the geographic reach of our sales and marketing efforts; |  | 30 [Table o","filed_date":"2024-03-28","accession":"0001140361-24-016230","full_text":"https://origin.rootz.global/static/filing/0001140361-24-016230.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"FEMY","company":"FEMASYS INC","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"ai_adoption","strength":32,"match_count":4,"context":"**Logo:** https://api.massive.com/v1/reference/company-branding/ZmVtYXN5cy5jb20/images/2025-04-04_logo.svg --- EX-99.1 2 ef20015647_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Femasys Inc. Completes Enrollment of FemaSeed Pivotal Trial in Support of Commercial Launch - Topline results from FemaSeed pivotal trial expected in 1H 2024 - - Commercial launch planned for early 2024 - ATLANTA, November 28, 202","filed_date":"2023-11-29","accession":"0001140361-23-055213","full_text":"https://origin.rootz.global/static/filing/0001140361-23-055213.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"FEMY","company":"FEMASYS INC","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"ai_adoption","strength":32,"match_count":4,"context":"(PMA)23Stage III: Pivotal Clinical Trial (IDE approved June 2023; currently enrolling)FINALE Trial Design:Prospective, multi-center, open-label, single-arm studyRoll-in study design to begin with enrollment of 50 women for a clinical readout primarily of preliminary safety data prior to enrolling remaining subjects.Primary Endpoint: pregnancy rate at 1-year after FemBloc use for permanent birth contr","filed_date":"2023-09-27","accession":"0001140361-23-045412","full_text":"https://origin.rootz.global/static/filing/0001140361-23-045412.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"FEMY","company":"FEMASYS INC","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"ai_adoption","strength":32,"match_count":4,"context":"es on couples experiencing male factor infertility. This update reflects a revised strategy to address this underserved population experiencing infertility with a goal of facilitating accelerated enrollment. Completion of enrollment is now expected in the fourth quarter of 2023 followed by a planned submission of the results from the trial to FDA in support of a future de novo classification request","filed_date":"2023-05-11","accession":"0001140361-23-024144","full_text":"https://origin.rootz.global/static/filing/0001140361-23-024144.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"FEMY","company":"FEMASYS INC","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"margin_pressure","strength":32,"match_count":4,"context":"roduct, if granted de novo classification; |  | |  |  |  Changes in coverage policies by third-party payors that affect the reimbursement of procedures using our products; |  | |  |  |  Unanticipated pricing pressure; |  | |  |  |  The hiring, retention and continued productivity of sales representatives; |  | |  |  |  Our ability to expand the geographic reach of our sales and marketing efforts; |  | |  |  |  Ou","filed_date":"2023-03-30","accession":"0001140361-23-014668","full_text":"https://origin.rootz.global/static/filing/0001140361-23-014668.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"FEMY","company":"FEMASYS INC","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"ai_adoption","strength":32,"match_count":4,"context":"development for the front end of infertility. The update reflected a revised strategy to address couples experiencing male factor infertility, with the additional goal of facilitating accelerated enrollment. |  | |  |  In November, Femasys announced that it completed over 25% of its targeted enrollment (214 patient fertility cycles) in this trial. |  | FemBloc |  |  In October, Femasys announced enro","filed_date":"2023-03-30","accession":"0001140361-23-014662","full_text":"https://origin.rootz.global/static/filing/0001140361-23-014662.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"FEMY","company":"FEMASYS INC","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"ai_adoption","strength":32,"match_count":4,"context":"ces industry related to fundraising, global product launches and corporate strategy. |  | First Quarter 2022 and Recent Developments Related to Clinical Programs |  |  Femasys expects to complete enrollment for its Stage 2 study of FemBloc in the third quarter of this year and file an IDE for a pivotal trial to support a PMA in the first quarter of next year. |  | |  |  An interim analysis for the Fe","filed_date":"2022-05-11","accession":"0001140361-22-018649","full_text":"https://origin.rootz.global/static/filing/0001140361-22-018649.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"FEMY","company":"FEMASYS INC","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"margin_pressure","strength":32,"match_count":4,"context":"roduct, if granted de novo classification; |  | |  |  |  changes in coverage policies by third-party payors that affect the reimbursement of procedures using our products; |  | |  |  |  unanticipated pricing pressure; |  | |  |  |  the hiring, retention and continued productivity of our sales representatives; |  | |  |  |  our ability to expand the geographic reach of our sales and marketing efforts; |  | |  |  |","filed_date":"2022-03-24","accession":"0001140361-22-011032","full_text":"https://origin.rootz.global/static/filing/0001140361-22-011032.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."}],"origin":{"leaf":"b2e1e65db039d34bc8a7bf48d9d17a0bcad263d8f6e27a304f34fba80d8707e3","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"b49ec36dfc75068a204cd16e9c615896ad05a228aa01775fb27981dde1c88731","parent":null,"source":"signal_search","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":9,"hourly_limit":500,"remaining":491,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}